In phase II clinical trials, Atacicept demonstrated a dose-dependent reduction in flare rates among patients with SLE, indicating that inhibiting both BAFF and APRIL can lead to improved clinical outcomes (200). The gene discussed is TNFSF13; the disease is systemic lupus erythematosus.